

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of November 2021**

**Commission File Number: 001-39316**

---

**BURNING ROCK BIOTECH LIMITED**  
(Registrant's Name)

---

**601, 6/F, Building 3, Standard Industrial Unit 2  
No.7 Luoxuan 4th Road, International Bio Island  
Guangzhou, Guangdong  
People's Republic of China  
(Address of principal executive offices)**

---

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F       Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

**EXHIBIT INDEX**

<b>Number</b>	<b>Description of Document</b>
99.1	<a href="#">Burning Rock Reports Third Quarter 2021 Financial Results</a>
99.2	<a href="#">Burning Rock Announces 2021 Annual General Meeting to be Held on December 28, 2021</a>
99.3	<a href="#">Notice of Annual General Meeting</a>
99.4	<a href="#">Form of Proxy for the Annual General Meeting</a>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Burning Rock Biotech Limited

By: /s/ Leo Li

Name: Leo Li

Title: Chief Financial Officer

Date: November 16, 2021

## Burning Rock Reports Third Quarter 2021 Financial Results

GUANGZHOU, China, November 16, 2021—Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2021.

### Business Updates

- **Early Detection**
  - 6-cancer product: we have successfully signed contracts with a small number of pilot hospitals in China for the commercialization of our 6-cancer early detection product, and will focus on customer education and contracting more hospitals.
  - 9-cancer product: we expect our 9-cancer early detection product development read-out in the first half of 2022, with potential performance improvement over that of our 6-cancer early detection product.
- **Pharma Services**
  - Pharma service contract backlog continues to build rapidly. The total value of new contracts we entered into during the nine months ended September 30, 2021 amounted to RMB144 million, which is approximately 4.5 times of the new contract value signed in full-year 2020.
  - Pharma projects involving our Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited laboratory in California continue to grow. For instance, in early November, we announced further collaboration with IMPACT Therapeutics where our Guangzhou and California laboratories would provide testing services in connection with IMPACT Therapeutics’ development of its ATR inhibitor IMP9064, which has received the Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for the Phase I/II clinical study.
- **Therapy Selection**
  - Continued execution of our strategic shift towards more in-hospital testing, with industry-leading scale and growth rate. The volume of in-hospital NGS-based test kits grew 37% year-over-year to over 11,000 tests during the third quarter of 2021, despite the negative COVID-19 impact in August.

### Third Quarter 2021 Financial Results

Revenues were RMB126.6 million (US\$19.7 million) for the three months ended September 30, 2021, representing a 2.2% increase from RMB123.9 million for the same period in 2020, or a 0.5% sequential decrease from RMB127.3 million for the three months ended June 30, 2021.

- Revenue generated from central laboratory business was RMB78.8 million (US\$12.2 million) for the three months ended September 30, 2021, representing a 12.3% decrease from RMB89.9 million for the same period in 2020, primarily attributable to a decrease in the number of patients tested in the central laboratory channel to 7,808 for the three months ended September 30, 2021, representing a 9.7% decrease from 8,644 for the same period in 2020.
- Revenue generated from in-hospital business was RMB43.7 million (US\$6.8 million) for the three months ended September 30, 2021, representing a 37.9% increase from RMB31.7 million for the same period in 2020, driven by in-hospital testing volume growth.
- Revenue generated from pharma research and development services was RMB4.1 million (US\$0.6 million) for the three months ended September 30, 2021, representing a 79.3% increase from RMB2.3 million for the same period in 2020, primarily attributable to increased testing performed for our pharma customers and growth in companion diagnostics development services.

Cost of revenues was RMB35.0 million (US\$5.4 million) for the three months ended September 30, 2021, representing an 8.4% increase from RMB32.3 million for the same period in 2020, which was generally in line with the Company’s continued business growth.

Gross profit was RMB91.6 million (US\$14.2 million) for the three months ended September 30, 2021, which was remained relatively stable compared to the same period in 2020. Gross margin was 72.3% for the three months ended September 30, 2021, compared to 73.9% for the same period in 2020.

Operating expenses were RMB262.6 million (US\$40.8 million) for the three months ended September 30, 2021, representing a 21.5% increase from RMB216.2 million for the same period in 2020. The increase was primarily driven by headcount growth to support our business expansion.

- Research and development expenses were RMB69.6 million (US\$10.8 million) for the three months ended September 30, 2021, representing a 0.5% increase from RMB69.3 million for the same period in 2020, primarily due to an increase in research and development personnel's staff cost resulted from an increase in headcount, partially offset by a decrease in share-based compensation for research and development personnel.
- Selling and marketing expenses were RMB76.7 million (US\$11.9 million) for the three months ended September 30, 2021, representing a 73.6% increase from RMB44.2 million for the same period in 2020, primarily due to an increase in staff cost resulted from increase in headcount to strengthen our commercial presence in the therapy selection business and build up our early detection commercialization team.
- General and administrative expenses were RMB116.3 million (US\$18.1 million) for the three months ended September 30, 2021, representing a 13.2% increase from RMB102.7 million for the same period in 2020, primarily due to an increase in general and administrative personnel's staff cost resulted from an increase in headcount and share-based compensation expenses.

Net loss was RMB170.5 million (US\$26.5 million) for the three months ended September 30, 2021, compared to RMB127.1 million for the same period in 2020.

Cash, cash equivalents, restricted cash and short-term investments were RMB1,685.4 million (US\$261.6 million) as of September 30, 2021.

## 2021 Financial Guidance

Starting late October, another wave of COVID resurgence has been reported in multiples cities in China, and the relevant governmental authorities have imposed travel restrictions and other measures. As of the date of this earnings release, the current wave has not been cleared out and the corresponding travel restrictions and other measures have not been lifted. We expect our central-laboratory testing volumes and, to a lesser extent, the growth of our in-hospital testing volumes, to be significantly impacted. We thus expect our 2021 full-year revenue to be at or around RMB500 million, subject to future development of the current wave of COVID resurgence.

## Conference Call Information

Burning Rock will host a conference call to discuss the third quarter 2021 financial results at 8:00 a.m. U.S. Eastern Time (9:00 p.m. Hong Kong time) on November 16, 2021.

Details of the conference call are as follows:

International:	+65 67135590
U.S.:	+1 3322089468
U.K.:	+44 2036928125
Hong Kong:	+852 30186771
China Mobile:	4008205286
China Landline:	8008208659
Conference ID:	2277434

A replay of the conference call will be available for one week (dial-in number: +61 2 8199 0299; same conference ID as shown above).

## About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 273,000 tissue and liquid-based tests completed cumulatively, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

---

For more information about Burning Rock, please visit: [ir.brbiotech.com](http://ir.brbiotech.com).

### **Safe Harbor Statement**

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contact: [IR@brbiotech.com](mailto:IR@brbiotech.com)

## Selected Operating Data

	For the three months ended						
	March 31, 2020	June 30, 2020	September 30, 2020	December 31, 2020	March 31, 2021	June 30, 2021	September 30, 2021
<b>Central Laboratory Channel:</b>							
Number of patients tested	4,680	7,252	8,644	7,989	7,716	8,155	7,808
Number of ordering physicians <sup>(1)</sup>	810	1,175	1,194	1,114	1,082	1,013	920
Number of ordering hospitals <sup>(2)</sup>	232	284	289	294	303	300	287

- (1) Represents physicians who on average order at least one test from us every month during a relevant period in the central laboratory channel.
- (2) Represents hospitals whose residing physicians who on average order at least one test from us every month during a relevant period in the central laboratory channel.

	As of						
	March 31, 2020	June 30, 2020	September 30, 2020	December 31, 2020	March 31, 2021	June 30, 2021	September 30, 2021
<b>In-hospital Channel:</b>							
Pipeline partner hospitals <sup>(1)</sup>	23	23	22	23	22	22	24
Contracted partner hospitals <sup>(2)</sup>	21	24	25	29	32	34	34
<b>Total number of partner hospitals</b>	<b>44</b>	<b>47</b>	<b>47</b>	<b>52</b>	<b>54</b>	<b>56</b>	<b>58</b>

- (1) Refers to hospitals that are in the process of establishing in-hospital laboratories, laboratory equipment procurement or installation, staff training or pilot testing using the Company's products.
- (2) Refers to hospitals that have entered into contracts to purchase the Company's products for use on a recurring basis in their respective in-hospital laboratories the Company helped them establish. Kit revenue is generated from contracted hospitals.

## Selected Financial Data

	For the three months ended						
	March 31, 2020	June 30, 2020	September 30, 2020	December 31, 2020	March 31, 2021	June 30, 2021	September 30, 2021
(RMB in thousands)							
<b>Revenues</b>							
Central laboratory channel	46,141	74,607	89,899	86,695	74,561	79,999	78,817
In-hospital channel	17,123	27,588	31,704	41,457	28,994	40,502	43,714
Pharma research and development channel	4,065	4,776	2,278	3,570	3,068	6,778	4,084
<b>Total revenues</b>	<b>67,329</b>	<b>106,971</b>	<b>123,881</b>	<b>131,722</b>	<b>106,623</b>	<b>127,279</b>	<b>126,615</b>

Gross profit	For the three months ended						
	March 31, 2020	June 30, 2020	September 30, 2020	December 31, 2020	March 31, 2021	June 30, 2021	September 30, 2021
	(RMB in thousands)						
Central laboratory channel	32,434	56,556	67,804	66,588	55,212	58,681	58,387
In-hospital channel	10,126	19,269	22,410	30,218	20,070	29,426	31,111
Pharma research and development channel	2,224	2,573	1,373	2,347	1,658	2,124	2,098
<b>Total gross profit</b>	<b>44,784</b>	<b>78,398</b>	<b>91,587</b>	<b>99,153</b>	<b>76,940</b>	<b>90,231</b>	<b>91,596</b>

Share-based compensation expenses	For the three months ended						
	March 31, 2020	June 30, 2020	September 30, 2020	December 31, 2020	March 31, 2021	June 30, 2021	September 30, 2021
	(RMB in thousands)						
Cost of revenues	176	183	160	277	339	406	267
Research and development expenses	2,072	25,314	10,572	11,843	22,404	20,825	(9,559)
Selling and marketing expenses	253	491	341	2,372	2,633	2,809	2,044
General and administrative expenses	1,665	1,639	57,805	58,057	59,382	59,369	60,803
<b>Total share-based compensation expenses</b>	<b>4,166</b>	<b>27,627</b>	<b>68,878</b>	<b>72,549</b>	<b>84,758</b>	<b>83,409</b>	<b>53,555</b>



**Burning Rock Biotech Limited**  
**Unaudited Condensed Statements of Comprehensive Loss**  
*(in thousands, except for number of shares and per share data)*

	For the three months ended							
	March 31, 2020 RMB	June 30, 2020 RMB	September 30, 2020 RMB	December 31, 2020 RMB	March 31, 2021 RMB	June 30, 2021 RMB	September 30, 2021 RMB	September 30, 2021 US\$
<b>Revenues</b>	<b>67,329</b>	<b>106,971</b>	<b>123,881</b>	<b>131,722</b>	<b>106,623</b>	<b>127,279</b>	<b>126,615</b>	<b>19,650</b>
<b>Cost of revenues</b>	<b>(22,545)</b>	<b>(28,573)</b>	<b>(32,294)</b>	<b>(32,569)</b>	<b>(29,683)</b>	<b>(37,048)</b>	<b>(35,019)</b>	<b>(5,435)</b>
<b>Gross profit</b>	<b>44,784</b>	<b>78,398</b>	<b>91,587</b>	<b>99,153</b>	<b>76,940</b>	<b>90,231</b>	<b>91,596</b>	<b>14,215</b>
<b>Operating expenses:</b>								
Research and development expenses	(40,016)	(71,176)	(69,330)	(83,418)	(77,414)	(108,071)	(69,649)	(10,809)
Selling and marketing expenses	(29,815)	(37,992)	(44,174)	(56,606)	(55,130)	(68,058)	(76,687)	(11,902)
General and administrative expenses	(34,295)	(42,272)	(102,731)	(114,502)	(116,259)	(116,130)	(116,304)	(18,050)
<b>Total operating expenses</b>	<b>(104,126)</b>	<b>(151,440)</b>	<b>(216,235)</b>	<b>(254,526)</b>	<b>(248,803)</b>	<b>(292,259)</b>	<b>(262,640)</b>	<b>(40,761)</b>
<b>Loss from operations</b>	<b>(59,342)</b>	<b>(73,042)</b>	<b>(124,648)</b>	<b>(155,373)</b>	<b>(171,863)</b>	<b>(202,028)</b>	<b>(171,044)</b>	<b>(26,546)</b>
Interest income	3,985	44	698	1,341	787	681	958	149
Interest expense	(1,178)	1,939	(776)	(652)	(510)	(565)	(367)	(57)
Other (expense) income, net	(151)	122	(176)	(682)	118	433	20	3
Foreign exchange loss, net	611	(118)	(2,228)	(1,112)	57	(560)	380	59
Change in fair value of warrant liability	3,503	—	—	—	—	—	—	—
<b>Loss before income tax</b>	<b>(52,572)</b>	<b>(71,055)</b>	<b>(127,130)</b>	<b>(156,478)</b>	<b>(171,411)</b>	<b>(202,039)</b>	<b>(170,053)</b>	<b>(26,392)</b>
Income tax expenses	—	—	—	—	—	(1,626)	(424)	(66)
<b>Net loss</b>	<b>(52,572)</b>	<b>(71,055)</b>	<b>(127,130)</b>	<b>(156,478)</b>	<b>(171,411)</b>	<b>(203,665)</b>	<b>(170,477)</b>	<b>(26,458)</b>
<b>Net loss attributable to Burning Rock Biotech Limited's shareholders</b>	<b>(52,572)</b>	<b>(71,055)</b>	<b>(127,130)</b>	<b>(156,478)</b>	<b>(171,411)</b>	<b>(203,665)</b>	<b>(170,477)</b>	<b>(26,458)</b>
Accretion of convertible preferred shares	(26,288)	(38,400)	—	—	—	—	—	—
<b>Net loss attributable to ordinary shareholders</b>	<b>(78,860)</b>	<b>(109,455)</b>	<b>(127,130)</b>	<b>(156,478)</b>	<b>(171,411)</b>	<b>(203,665)</b>	<b>(170,477)</b>	<b>(26,458)</b>
<b>Loss per share:</b>								
Ordinary shares - basic and diluted	(3.15)	—	—	—	—	—	—	—
Class A ordinary shares - basic and diluted	—	(2.68)	(1.22)	(1.51)	(1.65)	(1.96)	(1.64)	(0.25)
Class B ordinary shares - basic and diluted	—	(2.68)	(1.22)	(1.51)	(1.65)	(1.96)	(1.64)	(0.25)
<b>Weighted average shares outstanding used in loss per share computation:</b>								
Ordinary shares - basic and diluted	25,031,575	—	—	—	—	—	—	—
Class A ordinary shares - basic and diluted	—	23,461,319	86,479,686	86,511,799	86,721,263	86,764,260	86,908,975	86,908,975
Class B ordinary shares - basic and diluted	—	17,324,848	17,324,848	17,324,848	17,324,848	17,324,848	17,324,848	17,324,848
<b>Other comprehensive (loss) income, net of tax of nil:</b>								
Foreign currency translation adjustments	11,422	(2,336)	(91,093)	(94,881)	14,080	(34,980)	6,146	954
<b>Total comprehensive loss</b>	<b>(41,150)</b>	<b>(73,391)</b>	<b>(218,223)</b>	<b>(251,359)</b>	<b>(157,331)</b>	<b>(238,645)</b>	<b>(164,331)</b>	<b>(25,504)</b>
<b>Total comprehensive loss attributable to Burning Rock Biotech Limited's shareholders</b>	<b>(41,150)</b>	<b>(73,391)</b>	<b>(218,223)</b>	<b>(251,359)</b>	<b>(157,331)</b>	<b>(238,645)</b>	<b>(164,331)</b>	<b>(25,504)</b>

**Burning Rock Biotech Limited**  
**Unaudited Condensed Statements of Comprehensive Loss**

(in thousands, except for share and per share data)

	For the nine months ended		
	September 30, 2020	September 30, 2021	September 30, 2021
	RMB	RMB	USD
<b>Revenues</b>	<b>298,181</b>	<b>360,517</b>	<b>55,952</b>
<b>Cost of revenues</b>	<b>(83,412)</b>	<b>(101,750)</b>	<b>(15,791)</b>
<b>Gross profit</b>	<b>214,769</b>	<b>258,767</b>	<b>40,161</b>
<b>Operating expenses:</b>			
Research and development expenses	(180,522)	(255,134)	(39,596)
Selling and marketing expenses	(111,981)	(199,875)	(31,020)
General and administrative expenses	(179,298)	(348,693)	(54,116)
<b>Total operating expenses</b>	<b>(471,801)</b>	<b>(803,702)</b>	<b>(124,732)</b>
<b>Loss from operations</b>	<b>(257,032)</b>	<b>(544,935)</b>	<b>(84,571)</b>
Interest income	4,727	2,426	377
Interest expense	(15)	(1,442)	(224)
Other (expense) income, net	(205)	571	88
Foreign exchange loss, net	(1,735)	(123)	(19)
Change in fair value of warrant liability	3,503	—	—
<b>Loss before income tax</b>	<b>(250,757)</b>	<b>(543,503)</b>	<b>(84,349)</b>
Income tax expenses	—	(2,050)	(318)
<b>Net loss</b>	<b>(250,757)</b>	<b>(545,553)</b>	<b>(84,667)</b>
<b>Net loss attributable to Burning Rock Biotech Limited's shareholders</b>	<b>(250,757)</b>	<b>(545,553)</b>	<b>(84,667)</b>
Accretion of convertible preferred shares	(64,688)	—	—
<b>Net loss attributable to ordinary shareholders</b>	<b>(315,445)</b>	<b>(545,553)</b>	<b>(84,667)</b>
<b>Loss per share:</b>			
Class A ordinary shares - basic and diluted	(5.56)	(5.24)	(0.81)
Class B ordinary shares - basic and diluted	(5.56)	(5.24)	(0.81)
<b>Weighted average shares outstanding used in loss per share computation:</b>			
Class A ordinary shares - basic and diluted	39,446,747	86,798,854	86,798,854
Class B ordinary shares - basic and diluted	17,324,848	17,324,848	17,324,848
<b>Other comprehensive income (loss), net of tax of nil:</b>			
Foreign currency translation adjustments	(82,007)	(14,754)	(2,290)
<b>Total comprehensive loss</b>	<b>(332,764)</b>	<b>(560,307)</b>	<b>(86,957)</b>
<b>Total comprehensive loss attributable to Burning Rock Biotech Limited's shareholders</b>	<b>(332,764)</b>	<b>(560,307)</b>	<b>(86,957)</b>

**Burning Rock Biotech Limited**  
**Unaudited Condensed Consolidated Balance Sheets**

(In thousands)

	As of		
	December 31, 2020 RMB	September 30, 2021 RMB	September 30, 2021 US\$
<b>ASSETS</b>			
<b>Current assets:</b>			
Cash and cash equivalents	1,895,308	1,621,641	251,675
Restricted cash	29,898	28,069	4,356
Short-term investment	362,132	35,670	5,536
Accounts receivable, net	88,218	92,868	14,413
Contract assets	22,534	37,268	5,783
Amounts due from related parties	212	966	150
Inventories	68,021	115,785	17,970
Prepayments and other current assets	57,329	60,912	9,453
<b>Total current assets</b>	<b>2,523,652</b>	<b>1,993,179</b>	<b>309,336</b>
<b>Non-current assets:</b>			
Equity method investment	1,417	982	152
Property and equipment, net	111,481	296,383	45,999
Operating Right-of-use assets	—	86,813	13,473
Intangible assets, net	3,457	4,236	657
Other non-current assets	23,021	44,692	6,936
<b>Total non-current assets</b>	<b>139,376</b>	<b>433,106</b>	<b>67,217</b>
<b>TOTAL ASSETS</b>	<b>2,663,028</b>	<b>2,426,285</b>	<b>376,553</b>

**Burning Rock Biotech Limited**  
**Unaudited Condensed Consolidated Balance Sheets (Continued)**

(in thousands)

	December 31, 2020 RMB	As of September 30, 2021 RMB	September 30, 2021 US\$
<b>LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY</b>			
<b>Current liabilities:</b>			
Accounts payable	35,482	49,122	7,624
Deferred revenue	74,402	122,715	19,045
Capital lease obligations, current	4,816	—	—
Accrued liabilities and other current liabilities	83,648	90,966	14,116
Customer deposits	1,120	1,042	162
Short-term borrowing	7,370	7,370	1,144
Current portion of long-term borrowings	34,695	—	—
Current portion of operating lease liabilities	—	35,357	5,487
Current portion of financing lease liabilities	—	787	122
<b>Total current liabilities</b>	<b>241,533</b>	<b>307,359</b>	<b>47,700</b>
<b>Non-current liabilities:</b>			
Deferred government grants	263	—	—
Operating lease liabilities	—	57,530	8,929
Other non-current liabilities	228	227	35
<b>Total non-current liabilities</b>	<b>491</b>	<b>57,757</b>	<b>8,964</b>
<b>TOTAL LIABILITIES</b>	<b>242,024</b>	<b>365,116</b>	<b>56,664</b>
<b>Shareholders' equity:</b>			
Class A ordinary shares	116	116	18
Class B ordinary shares	21	21	3
Additional paid-in capital	4,006,616	4,220,944	655,080
Accumulated deficits	(1,418,160)	(1,977,569)	(306,913)
Accumulated other comprehensive loss	(167,589)	(182,343)	(28,299)
<b>Total shareholders' equity</b>	<b>2,421,004</b>	<b>2,061,169</b>	<b>319,889</b>
<b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b>	<b>2,663,028</b>	<b>2,426,285</b>	<b>376,553</b>

**Burning Rock Biotech Limited**  
**Unaudited Condensed Statements of Cash Flows**  
*(in thousands)*

	<b>For the three months ended</b>		
	<b>September 30,</b>	<b>September 30,</b>	<b>September 30,</b>
	<b>2020</b>	<b>2021</b>	<b>2021</b>
	<b>RMB</b>	<b>RMB</b>	<b>US\$</b>
Net cash generated from (used in) operating activities	(37,052)	(133,394)	(20,705)
Net cash generated from (used in) investing activities	(365,373)	(72,085)	(11,183)
Net cash generated from (used in) financing activities	(20,939)	(32,995)	(5,122)
Effect of exchange rate on cash, cash equivalents and restricted cash	(81,043)	4,919	763
<b>Net increase cash, cash equivalents and restricted cash</b>	<b>(504,407)</b>	<b>(233,555)</b>	<b>(36,247)</b>
Cash, cash equivalents and restricted cash at the beginning of period	2,566,236	1,883,265	292,278
<b>Cash, cash equivalents and restricted cash at the end of period</b>	<b>2,061,829</b>	<b>1,649,710</b>	<b>256,031</b>

	<b>For the nine months ended</b>		
	<b>September 30,</b>	<b>September 30,</b>	<b>September 30,</b>
	<b>2020</b>	<b>2021</b>	<b>2021</b>
	<b>RMB</b>	<b>RMB</b>	<b>US\$</b>
Net cash generated from (used in) operating activities	17,116	(365,537)	(56,728)
Net cash generated (used in) investing activities	(72,884)	148,667	23,071
Net cash generated from (used in) financing activities	2,097,242	(46,118)	(7,158)
Effect of exchange rate on cash, cash equivalents and restricted cash	(77,889)	(12,508)	(1,941)
<b>Net increase cash, cash equivalents and restricted cash</b>	<b>1,963,585</b>	<b>(275,496)</b>	<b>(42,756)</b>
Cash, cash equivalents and restricted cash at the beginning of period	98,244	1,925,206	298,787
<b>Cash, cash equivalents and restricted cash at the end of period</b>	<b>2,061,829</b>	<b>1,649,710</b>	<b>256,031</b>

**Burning Rock Announces 2021 Annual General Meeting to be Held on December 28, 2021**

GUANGZHOU, China, November 16, 2021—Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 28, 2021 at 10:00 a.m. (local time) at the Company’s Shanghai office at 5/F, Building 1, No. 138 Xinjunhuan Road, Minhang District, Shanghai and Cleary Gottlieb Steen & Hamilton (Hong Kong) at 37/F, Hysan Place, 500 Hennessy Road, Causeway Bay, Hong Kong.

The AGM will be held for the following proposals:

1. To ratify the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2021 and to authorize the directors of the Company to determine the remuneration of the auditor;
2. To re-elect Yusheng Han, Gang Lu and Shaokun Chuai as directors of the Company;
3. To approve, confirm and ratify the adoption of the 2021 Long-term Equity Incentive Plan and the grant of options thereunder, the vesting of which is tied to the Company’s future stock performances; and
4. To authorize each of the directors of the Company to take any and all action that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit.

The board of directors of the Company has fixed the close of business on November 17, 2021 (New York time) as the record date for determining the shareholders entitled to receive notice of the AGM or any adjournment or postponement thereof. Holders of record of the Company’s Class A ordinary shares or Class B ordinary shares, each with a par value of US\$0.0002 per share, at the close of business on the record date will be entitled to attend the AGM in either venue and any adjournment or postponement thereof in person.

The notice of the AGM and the Company’s 2020 Annual Report containing the complete audited financial statements and the report of auditors for the year ended December 31, 2020, is available on the Investor Relations Section of the Company’s website at <https://ir.brbiotech.com/>.

**About Burning Rock**

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 273,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

For more information about Burning Rock, please visit: [www.brbiotech.com](http://www.brbiotech.com).

---

**Safe Harbor Statement**

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contact: IR@brbiotech.com

## BURNING ROCK BIOTECH LIMITED

## NOTICE OF ANNUAL GENERAL MEETING TO BE HELD ON DECEMBER 28, 2021

**NOTICE IS HEREBY GIVEN** that the annual general meeting (the “AGM”) of Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) will be held on December 28, 2021 at the Company’s Shanghai office at 5/F, Building 1, No. 138 Xinjunhuan Road, Minhang District, Shanghai and Cleary Gottlieb Steen & Hamilton (Hong Kong) at 37/F, Hysan Place, 500 Hennessy Road, Causeway Bay, Hong Kong for the following purposes:

1. To ratify the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2021 and to authorize the directors of the Company to determine the remuneration of the auditor.
2. To re-elect Yusheng Han, Gang Lu and Shaokun Chuai as directors of the Company. The resume of each of Mr. Han, Mr. Lu and Ms. Chuai are attached hereto as Exhibit A.
3. To approve, confirm and ratify the adoption of the 2021 Long-term Equity Incentive Plan (attached hereto as Exhibit B) and the grant of options thereunder to purchase an aggregate of 12,533,016 Class A ordinary shares of the Company (the “Awards”), which represents approximately 10% of the Company’s current total outstanding shares on a converted and fully diluted basis, to officers and employees of the Company, with details as follows:

- **Vesting condition.** The Awards consist of two equal-sized tranches of options (the “Pool I Awards” and “Pool II Awards”):
  - The Pool I Awards will vest if (i) the valuation of the Company (based on the 60-day average closing share price of its publicly traded shares) reaches US\$10 billion by the fifth anniversary of the grant date, and (ii) the grantee remains employed by the Company when such valuation target is achieved; and
  - The Pool II Awards will vest if (i) the valuation of the Company (based on the 60-day average closing share price of its publicly traded shares) reaches US\$15 billion by the seventh anniversary of the grant date, and (ii) the grantee remains employed by the Company when such valuation target is achieved.

If a valuation target is achieved in whole or in part via change of the Company’s capital structure of over US\$1 billion in aggregate and/or acquisition of over US\$1 billion in aggregate, the Board may determine in its sole discretion whether this vesting condition is satisfied at a board meeting, where management board members shall abstain from voting.

No dilution will occur if the Awards are not exercised.

- **Exercise price.** The exercise price per share for all Awards will be the Company’s 60-day average closing share price immediately prior to the date of shareholder approval.
- **Allocation.** The Awards will be allocated as follows:
  - 45% of the Awards will be granted to Mr. Yusheng Han, the Company’s chairman and CEO;
  - 45.5% of the Awards will be granted to other officers and employees of the Company, details of which will be determined by the Board; and
  - The remaining 9.5% will be reserved for future grants to officers and employees of the Company, details of which will be determined by the compensation committee.
- **Voting abstention.** The adoption of the 2021 Long-term Equity Incentive Plan and the grant of the Awards have been approved at a board meeting, where Mr. Han and other management board members abstained from voting. Mr. Han, the Company’s other C-level officers and/or entities they beneficially own will abstain from voting for this resolution at the AGM.



Please note the Company is actively exploring and may continue to explore fund raising opportunities such as equity financing, as well as share repurchase transactions. Such transactions, if materialized, may have a positive impact on the Company's stock price.

4. To authorize each of the directors of the Company to take any and all action that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit.

#### **ORDINARY SHARES RECORD DATE AND ADS RECORD DATE**

The board of directors of the Company has fixed the close of business on November 17, 2021 (New York time) as the record date for determining the shareholders entitled to receive notice of the annual general meeting or any adjournment or postponement thereof. Holders of record of the Company's Class A ordinary shares or Class B ordinary shares, each with a par value of US\$0.0002 per share, at the close of business on the record date will be entitled to attend the annual general meeting in either venue and any adjournment or postponement thereof in person.

Holders of record of American Depositary Shares (the "ADSs") as of the close of business on November 17, 2021 (New York time) (the "ADS Record Date") who wish to exercise their voting rights for the underlying Class A ordinary shares must give voting instructions to Citibank, N.A., the depository of the ADSs.

#### **ATTENDING THE AGM**

Only holders of record of Class A ordinary shares or Class B ordinary shares as of the record date are entitled to attend and vote at the AGM. Please note that holders of ADSs are not entitled to attend the AGM. Any ADS holder who appears at the venue of the AGM will not be allowed to attend the AGM.

Any holder of Class A ordinary shares or Class B ordinary shares and any duly appointed proxy or corporate representative of a holder of ordinary shares, or any other person claiming a right to attend the AGM, must be, and must appear to be healthy to attend the AGM both at the point of entry and throughout the proceedings of the meeting. Any person who is not in such condition at all relevant times, or who does not comply with any precautionary measures being implemented, in each case in the reasonable view of any officer or agent of the Company, may be refused entry to the AGM, or may be instructed to leave the AGM at any time. All officers and agents of the Company reserve the right to refuse any person entry to the AGM, or to instruct any person to leave the AGM, where such officer or agent reasonably considers that such refusal or instruction is or may be required for the Company to be able to comply with applicable laws and regulations. The exercise of such right to refuse entry or instruct to leave shall not invalidate the proceedings at the AGM.

#### **PROXY FORMS AND ADS VOTING**

If you are a holder of our Class A ordinary shares or Class B ordinary shares on the Record Date, you are cordially invited to attend the annual general meeting in person. Your vote is important. If you cannot attend the annual general meeting in person, you are urged to complete, sign, date and return the accompanying form of proxy by mail to 5/F, Building 1, No. 138 Xinjunhuan Road, Minhang District, Shanghai, Attention: Michelle Zhou, Director of Corporate Finance, by email to [michelle.zhou@brbiotech.com](mailto:michelle.zhou@brbiotech.com) as soon as possible and in any event no later than 10:00 a.m. December 21, 2021 (New York time).

If you are a registered holder of our ADSs as at the Record Date, the depository, CITIBANK, N.A., (the "Depository") will forward to you the information of our annual general meeting and ask you to provide your voting instructions with respect to the shares represented by your ADSs. Holders of our ADSs who wish to exercise their voting rights for the underlying shares must act through the Depository. For your voting instructions to be valid, you must comply with the instructions provided by or on behalf of the Depository, and the Depository must receive your voting instructions in the manner and on or before the date specified (the "ADS Voting Instructions Deadline"). Voting at any meeting of shareholders is by show of hands unless a poll is demanded. In the event voting takes place at a shareholders' meeting by show of hands, the Depository will instruct CITIBANK N.A.— HONG KONG (the "Custodian") to vote all shares in accordance with the voting instructions received from a majority of holders of ADSs who provided voting instructions. In the event voting takes place at a shareholders' meeting by poll, the Depository will instruct the Custodian to vote the shares in accordance with the voting instructions received from the holders of ADSs. The Depository will only vote or attempt to vote as you instruct and as further described below.

Please note that if the Depositary does not receive instructions from a holder as of the Record Date on or before the ADS Voting Instructions Deadline and voting is by poll, such holder shall be deemed, and the Depositary shall deem such holder, to have instructed the Depositary to give a discretionary proxy to a person designated by the Company to vote the shares, provided, however, that no such discretionary proxy shall be given by the Depositary with respect to any matter to be voted upon as to which the Company informs the Depositary that (A) the Company does not wish such proxy to be given, (B) substantial opposition exists, or (C) the rights of holders of shares may be adversely affected. The Depositary will not itself exercise any voting discretion. Furthermore, neither the Depositary nor its agents are responsible for any failure to carry out any voting instructions, for the manner in which any vote is cast or for the effect of any vote.

BY ORDER OF THE BOARD OF DIRECTORS

/s/ Yusheng Han

Yusheng Han

Chairman of the Board of Directors

Date: November 16, 2021

## Exhibit A

### **Resume of Candidates for Directors**

*Mr. Yusheng Han* is our founder, chairman of the board of directors and chief executive officer. Mr. Han has 16 year of experience in life science. From June 2011 to November 2013, he was an associate in Northern Light Venture Capital where he focused on investment in the healthcare industry and helped the firm invest in successful companies. From July 2005 to May 2009, Mr. Han worked at BioTek Instruments, Inc. as its general manager in China. During his term with BioTek Instruments China, he built and led teams across marketing, sales and post-sale. From September 2003 to May 2005, he served as the product specialist of Gene Company Limited. Mr. Han received a bachelor's degree in biochemistry from Jilin University in July 2000, and a master's degree in cell biology in Peking Union Medical College in June 2003. He obtained a Master of Business Administration degree from Columbia Business School in May 2011.

*Mr. Gang Lu* has served as our director since June 2014. In 2009, Mr. Lu joined Legend Star, a venture capital headquartered in Beijing, and he is now a partner of Legend Star and leads investment in healthcare, specialized in the fields of innovative medicine, biological and genetic technology, and innovative medical service. Mr. Lu holds a bachelor's degree in electromagnetic engineering from Xidian University and a Master of Business Administration degree from Tsinghua University.

*Dr. Shaokun (Shannon) Chuai* has served as our director since August 2016. Dr. Chuai joined us as chief technology officer in May 2014 and she was appointed the chief operating officer in March 2016. Prior to joining us, she worked at China Novartis Institutes for BioMedical Research (CNIBR), responsible for the bioinformatics and translational research platform, and Novartis Oncology as the principal statistician for phase III clinical trials of targeted drugs. From June 2003 to June 2005, she worked at Memorial Sloan-Kettering Cancer Center as research statistician, responsible for omics data mining and clinical trial design. Dr. Chuai holds a bachelor's degree from Nankai University, a master's degree in statistics and applied mathematics from Texas A&M University, and a Ph.D. degree in biostatistics from the University of Pennsylvania.

**Burning Rock Biotech Limited 2021 Long-term Equity Incentive Plan**

**1. Purpose of the Plan**

The purpose of this Burning Rock Biotech Limited 2021 Long-Term Equity Incentive Plan (the “Plan”) is to aid the Company and its Affiliates in recruiting and retaining key employees or directors of outstanding ability and to motivate such employees or directors to exert their best efforts on behalf of the Company and its Affiliates by providing incentives through the granting of Awards. The Company expects that it will benefit from the added interest which such key employees or directors will have in the welfare of the Company as a result of their proprietary interest in the Company’s success.

**2. Definitions**

The following capitalized terms used in the Plan have the respective meanings set forth in this Section:

- (a) **Applicable Laws:** All laws, statutes, regulations, ordinances, rules or governmental requirements that are applicable to this Plan or any Award granted pursuant to this Plan, including but not limited to applicable laws of the People’s Republic of China, the United States and the Cayman Islands, and the rules and requirements of any applicable national securities exchange.
- (b) **Act:** The U.S. Securities Exchange Act of 1934, as amended, or any successor thereto.
- (c) **Affiliate:** With respect to the Company, any entity directly or indirectly controlling, controlled by, or under common control with, the Company or any other entity designated by the Board in which the Company or an Affiliate has an interest.
- (d) **Award:** An Option award granted to a Participant pursuant to the Plan.
- (e) **Beneficial Owner:** A “beneficial owner”, as such term is defined in Rule 13d-3 under the Act (or any successor rule thereto).
- (f) **Board:** The board of directors of the Company.
- (g) **Change of Control:** The occurrence of any of the following events:
  - (i) the sale or disposition, in one or a series of related transactions, of all or substantially all, of the assets of the Company to any “person” or “group” (as such terms are defined in Sections 13(d)(3) or 14(d)(2) of the Act) other than the Permitted Holders;
  - (ii) any person or group, other than the Permitted Holders, is or becomes the Beneficial Owner (except that a person shall be deemed to have “beneficial ownership” of all shares that any such person has the right to acquire, whether such right is exercisable immediately or only after the passage of time), directly or indirectly, of more than 50% of the total outstanding shares of the Company (or any entity which controls the Company), including by way of merger, consolidation, tender or exchange offer or otherwise; or

- (iii) during any period of two consecutive years, individuals who at the beginning of such period constituted the Board (together with any new directors whose election by such Board or whose nomination for election by the shareholders of the Company was approved by a vote of a majority of the directors of the Company, then still in office, who were either directors at the beginning of such period or whose election or nomination for election was previously so approved) cease for any reason to constitute a majority of the Board, then in office.
- (h) **Code:** The U.S. Internal Revenue Code of 1986, as amended, or any successor thereto.
- (i) **Committee:** The compensation committee of the Board.
- (j) **Company:** Burning Rock Biotech Limited, a company incorporated under the laws of the Cayman Islands.
- (k) **Disability:** Inability of a Participant to perform in all material respects his duties and responsibilities to the Company, or any Subsidiary of the Company, by reason of a severe physical or mental disability or infirmity which inability is reasonably expected to be permanent and has continued (i) for a period of not less than 90 consecutive days or (ii) such shorter period as the Committee may reasonably determine in good faith. The Disability determination shall be in the sole discretion of the Committee and a Participant (or his representative) shall furnish the Committee with medical evidence documenting the Participant's disability or infirmity which is satisfactory to the Committee.
- (l) **Effective Date:** The date the Plan is approved at a shareholders' general meeting.
- (m) **Employment:** The term "Employment" as used herein shall be deemed to refer to (i) a Participant's employment if the Participant is an employee of the Company or any of its Affiliates, and (ii) a Participant's services as a non-employee director, if the Participant is a non-employee member of the Board.
- (n) **Fair Market Value:** On a given date, (i) if there should be a public market for the Shares on such date, the closing price of the Shares as reported on such date on the principal national securities exchange on which such Shares are listed or admitted to trading, or (ii) if there should not be a public market for the Shares on such date, the Fair Market Value shall be the value established by the Committee in good faith.
- (o) **ISO:** An Option that is also an incentive share option granted pursuant to Section 6(e) of the Plan.
- (p) **Option:** A share option granted pursuant to Section 6 of the Plan.
- (q) **Participant:** An employee or director who is selected by the Committee to participate in the Plan.

- (r) **Permitted Holder:** means, as of the date of determination, (i) the Company or (ii) any employee benefit plan (or trust forming a part thereof) maintained by (A) the Company or (B) any corporation or other Person of which a majority of its voting power or its voting equity securities or equity interest is owned, directly or indirectly, by the Company.
- (s) **Person:** A “person”, as such term is used for purposes of Section 13(d) or 14(d) of the Act (or any successor section thereto).
- (t) **Plan:** This Burning Rock Biotech Limited 2021 Long-term Equity Incentive Plan.
- (u) **Shares:** Class A ordinary shares of the Company, par value US\$0.0002 per share.
- (v) **Subsidiary:** A corporation or other entity of which a majority of the outstanding voting shares or voting power is beneficially owned directly or indirectly by the Company.

### 3. Shares Subject to the Plan

The total number of Shares which may be issued under the Plan is 12,533,016 (which will be equitably adjusted in the event of any share dividend, subdivision, reclassification, recapitalization, split, reverse split, combination, consolidation or similar transactions). The Shares may consist, in whole or in part, of authorized and unissued Shares or Shares purchased on the open market. The issuance of Shares or the payment of cash upon the exercise of an Award or in consideration of the cancellation or termination of an Award shall reduce the total number of Shares available under the Plan, as applicable. Shares which are subject to Awards which terminate or lapse without the payment of consideration may be granted again under the Plan.

### 4. Administration

The compensation committee shall have the full power and authority to establish the terms and conditions of any Award consistent with the provisions of the Plan, except for the Awards that have already been allocated (the “Allocated Awards”). The Allocated Awards can only be amended at a shareholders’ general meeting, at which meeting the Company’s C-level officers and/or entities they beneficially own shall abstain from voting.

### 5. Limitations

No Award may be granted under the Plan after the tenth anniversary of the Effective Date, but Awards theretofore granted may extend beyond that date.

### 6. Terms and Conditions of Options

Options granted under the Plan shall be, as determined by the Committee, non-qualified or incentive share options for U.S. federal income tax purposes, as evidenced by the related Award agreements, and shall be subject to the foregoing and the following terms and conditions and to such other terms and conditions, not inconsistent therewith, as the Committee shall determine:

- (a) **Exercise Price.** The exercise price per Share subject to an Option shall be the 60-day average closing share price of the Company immediately prior to the date of shareholder approval (which will be equitably adjusted in the event of any share dividend, subdivision, reclassification, recapitalization, split, reverse split, combination, consolidation or similar transactions).

- (b) Vesting Conditions. Subject to any additional vesting conditions which may be imposed by the Committee, Options granted under the Plan will vest if:
- 1) the Company meets the relevant valuation target(s) as specified in the Award agreements. If the relevant valuation target(s) are not met within five (5) or seven (7) years from the date of grant of such Options, the corresponding Options will expire on the fifth or seventh anniversary of the date of grant and can no longer be exercised; and
  - 2) The Participant remains employed by the Company when the relevant valuation target is met. If the Participant's Employment with the Company is terminated before the relevant valuation target is met, his/her Options will be automatically canceled without consideration and can no longer be exercised.
- (c) Exercisability. Options granted under the Plan shall be exercisable at such time and upon such additional terms and conditions as may be determined by the Committee, but in no event shall an Option be exercisable more than ten years after the date it is granted.
- (d) Exercise of Options. Except as otherwise provided in the Plan or in an Award agreement, an Option may be exercised for all, or from time to time any part, of the Shares for which it is then exercisable. For purposes of this Section 6 of the Plan, the exercise date of an Option shall be the later of the date a notice of exercise is received by the Company and, if applicable, the date payment is received by the Company pursuant to clauses (i), (ii), (iii) or (iv) in the following sentence. The purchase price for the Shares as to which an Option is exercised shall be paid to the Company in full at the time of exercise at the election of the Participant (i) in cash or its equivalent (e.g., by check), (ii) to the extent permitted by the Committee, in Shares having a Fair Market Value equal to the aggregate exercise price for the Shares being purchased and satisfying such other requirements as may be imposed by the Committee; provided, that such Shares have been held by the Participant for no less than six months (or such other period as established from time to time by the Committee in order to avoid adverse accounting treatment applying generally accepted accounting principles), (iii) partly in cash and, to the extent permitted by the Committee and subject to the other requirements and conditions set forth above in (ii), partly in Shares or (iv) if there is a public market for the Shares at such time, through the delivery of irrevocable instructions to a broker to sell Shares obtained upon the exercise of the Option and to deliver promptly to the Company an amount out of the proceeds of such sale equal to the aggregate exercise price for the Shares being purchased. No Participant shall have any rights to dividends or other rights of a shareholder with respect to Shares subject to an Option until the Participant has given written notice of exercise of the Option, paid in full for such Shares and, if applicable, has satisfied any other conditions imposed by the Committee pursuant to the Plan.

- (e) **ISOs.** The Committee may grant Options under the Plan that are intended to be ISOs. Such ISOs shall comply with the requirements of Section 422 of the Code (or any successor section thereto). No ISO may be granted to any Participant who at the time of such grant, owns more than ten percent of the total combined voting power of all classes of shares of the Company or of any Subsidiary, unless (i) the exercise price for such ISO is at least 110% of the Fair Market Value of a Share on the date the ISO is granted and (ii) the date on which such ISO terminates is a date not later than the day preceding the fifth anniversary of the date on which the ISO is granted. Any Participant who disposes of Shares acquired upon the exercise of an ISO either (i) within two years after the date of grant of such ISO or (ii) within one year after the transfer of such Shares to the Participant, shall notify the Company of such disposition and of the amount realized upon such disposition. All Options granted under the Plan are intended to be nonqualified share options, unless the applicable Award agreement expressly states that the Option is intended to be an ISO. If an Option is intended to be an ISO, and if for any reason such Option (or portion thereof) shall not qualify as an ISO, then, to the extent of such nonqualification, such Option (or portion thereof) shall be regarded as a nonqualified share option granted under the Plan; provided that such Option (or portion thereof) otherwise complies with the Plan's requirements relating to nonqualified share options. In no event shall any member of the Committee, the Company or any of its Affiliates (or their respective employees, officers or directors) have any liability to any Participant (or any other Person) due to the failure of an Option to qualify for any reason as an ISO.
- (f) **Attestation.** Wherever in this Plan or any agreement evidencing an Award a Participant is permitted to pay the exercise price of an Option or taxes relating to the exercise of an Option by delivering Shares, the Participant may, subject to procedures satisfactory to the Committee, satisfy such delivery requirement by presenting proof of beneficial ownership of such Shares, in which case the Company shall treat the Option as exercised without further payment and shall withhold such number of Shares from the Shares acquired by the exercise of the Option.

## 7. Adjustments Upon Certain Events

Notwithstanding any other provisions in the Plan to the contrary, the following provisions shall apply to all Awards granted under the Plan:

- (a) **Generally.** In the event of any change in the outstanding Shares after the Effective Date by reason of any Share dividend or split, reorganization, recapitalization, merger, consolidation, spin-off, combination or transaction or exchange of Shares or other corporate exchange, or any distribution to shareholders of Shares other than regular cash dividends or any transaction similar to the foregoing, the Committee in its sole discretion and without liability to any person shall make such substitution or adjustment, if any, as it deems to be equitable, as to (i) the number or kind of Shares or other securities issued or reserved for issuance pursuant to the Plan or pursuant to outstanding Awards, (ii) the maximum number of Shares for which Awards may be granted during a calendar year to any Participant, (iii) the exercise price of any Award and/or (iv) any other affected terms of such Awards.



- (b) Change of Control. In the event of a Change of Control after the Effective Date, (i) any outstanding Awards then held by Participants which are unexercisable or otherwise unvested or subject to lapse restrictions shall automatically be deemed exercisable or otherwise vested or no longer subject to lapse restrictions, as the case may be, as of immediately prior to such Change of Control and (ii) the Committee may, but shall not be obligated to, (A) cancel such Awards for fair value (as determined in the sole discretion of the Committee) which, in the case of Options, may equal the excess, if any, of value of the consideration to be paid in the Change of Control transaction to holders of the same number of Shares subject to such Options (or, if no consideration is paid in any such transaction, the Fair Market Value of the Shares subject to such Options) over the aggregate exercise price of such Options, or (B) provide for the issuance of substitute Awards that will substantially preserve the otherwise applicable terms of any affected Awards previously granted hereunder as determined by the Committee in its sole discretion.

#### **8. No Right to Employment or Awards, No Shareholders Rights**

The granting of an Award under the Plan shall impose no obligation on the Company or any Subsidiary to continue the Employment of a Participant and shall not lessen or affect the Company's or Subsidiary's right to terminate the Employment of such Participant. No Participant or other Person shall have any claim to be granted any Award, and there is no obligation for uniformity of treatment of Participants, or holders or beneficiaries of Awards. The terms and conditions of Awards and the Committee's determinations and interpretations with respect thereto need not be the same with respect to each Participant (whether or not such Participants are similarly situated).

Unless as specified in the Award agreements, no Award gives the Participant any of the rights of a shareholder of the Company unless and until Shares are in fact issued to such person in connection with such Award.

#### **9. Successors and Assigns**

The Plan shall be binding on all successors and assigns of the Company and a Participant, including without limitation, the estate of such Participant and the executor, Committee or trustee of such estate, or any receiver or trustee in bankruptcy or representative of the Participant's creditors.

#### **10. Nontransferability of Awards**

Unless otherwise determined by the Committee, an Award shall not be transferable or assignable by the Participant otherwise than by will or by the laws of descent and distribution. An Award exercisable after the death of a Participant may be exercised by the legatees, personal representatives or distributees of the Participant.

The above transfer restrictions will not apply to (a) transfer to the Company or a Subsidiary; (b) transfers by gift to "immediate family" as that term is defined in SEC Rule 16a-1(e) promulgated under the Exchange Act, (c) the designation of a beneficiary to receive benefits if the Participant dies or, if the Participant has died, transfers to or exercises by the Participant's beneficiary, or, in the absence of a validly designated beneficiary, transfers by will or the laws of descent and distribution; or (d) transfer to one or more natural persons who are the Participant's family members or entities owned and controlled by the Participant and/or the Participant's family members, including but not limited to trusts or other entities whose beneficiaries or beneficial owners are the Participant and/or the Participant's family members, or to such other persons or entities as may be expressly approved by the Committee, pursuant to such conditions and procedures as the Committee or may establish.

## **11. Amendments or Termination**

The Board may amend, alter or discontinue the Plan, but no amendment, alteration or discontinuation shall be made, (a) without the approval of the shareholders of the Company, if such action would (except as is provided in Section 7 of the Plan), increase the total number of Shares reserved for the purposes of the Plan or change the maximum number of Shares for which Awards may be granted to any Participant, in each case only to the extent such approval is required by the principal national securities exchange on which the Shares are listed or admitted to trading, or (b) without the consent of a Participant, if such action would diminish any of the rights of the Participant under any Award theretofore granted to such Participant under the Plan; provided, however, that the Committee may amend the Plan in such manner as it deems necessary to permit the granting of Awards meeting the requirements of any Applicable Laws.

Without limiting the generality of the foregoing, to the extent applicable, notwithstanding anything herein to the contrary, this Plan and Awards issued hereunder shall be interpreted in accordance with Section 409A of the Code and Department of Treasury regulations and other interpretative guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Effective Date. Notwithstanding any provision of the Plan to the contrary, in the event that the Committee determines that any amounts payable hereunder will be taxable to a Participant under Section 409A of the Code and related Department of Treasury guidance prior to payment to such Participant of such amount, the Company may (a) adopt such amendments to the Plan and Awards and appropriate policies and procedures, including amendments and policies with retroactive effect, that the Committee determines necessary or appropriate to preserve the intended tax treatment of the benefits provided by the Plan and Awards hereunder and/or (b) take such other actions as the Committee determines necessary or appropriate to comply with the requirements of Section 409A of the Code.

Notwithstanding the foregoing, any Allocated Awards can only be amended at a shareholders' general meeting, at which meeting the Company's C-level officers and/or entities they beneficially own shall abstain from voting.

## **12. Multiple Jurisdictions**

In order to assure the viability of Awards granted to Participants employed in various jurisdictions, the Committee may, in its sole discretion, provide for such special terms as it may consider necessary or appropriate to accommodate differences in local law, tax policy or custom applicable in the jurisdiction in which the Participant resides or is employed. Moreover, the Committee may approve such supplements to, amendments, restatements, or alternative versions of the Plan as it may consider necessary or appropriate for such purposes without thereby affecting the terms of the Plan as in effect for any other purpose; provided, however, that no such supplements, amendments, restatements or alternative versions shall increase the Share limitation contained in Section 3 hereof. Notwithstanding the foregoing, the Committee may not take any actions hereunder, and no Awards shall be granted that would violate any Applicable Laws.

### **13. Distribution of Shares**

The obligation of the Company to make payments in Shares pursuant to an Award shall be subject to all Applicable Laws and to any such approvals by government agencies as may be required. Additionally, in the discretion of the Participant, American depositary shares, or ADSs, may be distributed in lieu of Shares in settlement of any Award, provided that the ADSs shall be of equal value to the Shares that would have otherwise been distributed. If the number of Shares represented by an ADS is other than on a one-to-one basis, the limitations contained in Section 3 shall be adjusted to reflect the distribution of ADSs in lieu of Shares.

### **14. Taxes**

No Shares shall be delivered under the Plan to any Participant until such Participant has made arrangements acceptable to the Committee for the satisfaction of any income and employment tax withholding obligations under any Applicable Laws, in particular, the tax laws, rules, regulations and government orders of the People's Republic of China or the U.S. federal, state or other local tax laws, as applicable. The Company and each of its Subsidiaries shall have the authority and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy federal, state, local and foreign taxes (including the Participant's payroll tax obligations, if any) required to be withheld under any Applicable Laws with respect to any Award issued to the Participant hereunder. The Committee may in its discretion and in satisfaction of the foregoing requirement allow a Participant to elect to have the Company withhold Shares otherwise issuable under an Award (or allow the return of Shares) having a Fair Market Value equal to the sums required to be withheld. Notwithstanding any other provision of the Plan, the number of Shares which may be withheld with respect to the issuance, vesting, exercise or payment of any Award (or which may be repurchased from the Participant of such Award after such Shares were acquired by the Participant from the Company) in order to satisfy the Participant's federal, state, local and other income and payroll tax liabilities with respect to the issuance, vesting, exercise or payment of the Award shall, unless specifically approved by the Committee, be limited to the number of Shares which have a Fair Market Value on the date of withholding or repurchase equal to the aggregate amount of such liabilities based on the minimum statutory withholding rates for federal, state, local and other income tax any payroll tax purposes that are applicable to such taxable income.

### **15. Choice of Law**

The Plan shall be governed by and construed in accordance with the laws of the Cayman Islands.

### **16. Effectiveness of the Plan**

The Plan shall be effective as of the Effective Date and shall terminate ten years later, subject to earlier termination by the Board pursuant to Section 11 hereof.

## BURNING ROCK BIOTECH LIMITED

**FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON DECEMBER 28, 2021 (OR ANY ADJOURNMENTS OR POSTPONEMENTS THEREOF)****Introduction**

This Form of Proxy is furnished in connection with the solicitation by the Board of Directors of Burning Rock Biotech Limited, an exempted company incorporated in the Cayman Islands with limited liability (the “Company”), of proxies from the holders of the issued Class A ordinary shares and Class B ordinary shares, each with par value US\$0.0002 per share of the Company (the “Ordinary Shares”) to be exercised at the annual general meeting of the Company (the “AGM”) to be held on December 28, 2021 at 10:00 a.m. (local time) at the Company’s Shanghai office at 5/F, Building 1, No. 138 Xinjunhuan Road, Minhang District, Shanghai and Cleary Gottlieb Steen & Hamilton (Hong Kong) at 37/F, Hysan Place, 500 Hennessy Road, Causeway Bay, Hong Kong, and at any adjourned meeting thereof, for the purposes set forth in the accompanying Notice of Annual General Meeting (the “AGM Notice”).

Only the holders of record of the Ordinary Shares at the close of business on November 17, 2021 (the “Record Date”) are entitled to notice of and to vote at the AGM. In respect of the matters requiring shareholders’ vote at the AGM, each holder of Class A ordinary shares is entitled on a poll to one vote for every such share held by him and each holder of Class B ordinary shares is entitled on a poll to six votes for every such share held by him. The quorum for the AGM is one or more shareholders entitled to vote at the AGM and present in person or by proxy or (in the case of a shareholder being a corporation or other non-natural person) by its duly authorized representative representing not less than one-third of all votes attaching to all Ordinary Shares in issue and entitled to vote in the Company throughout the meeting.

The Ordinary Shares represented by all properly executed proxies returned to the Company will be voted at the AGM as indicated or, if no instruction is given, the holder of the proxy will vote the shares in his discretion, unless a reference to the holder of the proxy having such discretion has been deleted and initialed on this Form of Proxy. Where the chairman of the AGM acts as proxy and is entitled to exercise his discretion, he is likely to vote the shares FOR the resolutions. As to any other business that may properly come before the AGM, all properly executed proxies will be voted by the persons named therein in accordance with their discretion. The Company does not presently know of any other business which may come before the AGM. However, if any other matter properly comes before the AGM, or any adjourned meeting thereof, which may properly be acted upon, unless otherwise indicated the proxies solicited hereby will be voted on such matter in accordance with the discretion of the proxy holders named therein. Any person giving a proxy has the right to revoke it at any time before it is exercised (i) by filing with the Company a duly signed revocation at 5/F, Building 1, No. 138 Xinjunhuan Road, Minhang District, Shanghai, attention: Michelle Zhou, Director of Corporate Finance, by email to [michelle.zhou@brbiotech.com](mailto:michelle.zhou@brbiotech.com) or (ii) by attending and voting in person at the AGM.

**To be valid, this Form of Proxy must be completed, signed and returned to 5/F, Building 1, No. 138 Xinjunhuan Road, Minhang District, Shanghai, Attention: Michelle Zhou, Director of Corporate Finance, by email to [michelle.zhou@brbiotech.com](mailto:michelle.zhou@brbiotech.com) as soon as possible and in any event no later than 10:00 a.m. December 21, 2021 (New York time).**

**BURNING ROCK BIOTECH LIMITED**

**FORM OF PROXY FOR THE ANNUAL GENERAL MEETING**

to Be Held on December 28, 2021  
(or any adjourned meeting thereof)

We, \_\_\_\_\_ of \_\_\_\_\_, being the registered holder of \_\_\_\_\_ [Class A/Class B] ordinary shares, each with par value US\$0.0002 per share ( the “Shares”)<sup>1</sup> of Burning Rock Biotech Limited (“the Company”) hereby appoint \_\_\_\_\_, or failing him/her, the Chairman of the AGM<sup>2</sup>, as our proxy to attend and act on our behalf at the annual general meeting of the Company to be held on December 28, 2021 at 10:00 a.m. (local time), and at any adjournment(s) or postponement(s) thereof. Our proxy is instructed to vote on a poll or on a show of hands on the resolutions in respect of the matters specified in the Notice of the Annual General Meeting as indicated below, or if no such indication is given, as my/our proxy thinks fit<sup>3</sup>:

<u>No.</u>	<u>RESOLUTIONS</u>	<u>FOR</u>	<u>AGAINST</u>	<u>ABSTAIN</u>
1.	That the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2021 be ratified and that directors of the Company be authorized to determine the remuneration of the auditor.			
2.	That Yusheng Han, Gang Lu and Shaokun Chuai be re-elected as directors of the Company.			
3.	That the 2021 Long-term Equity Incentive Plan and the grants of options thereunder be and is hereby approved and confirmed, and where necessary ratified			
4.	That each of the directors of the Company be authorized to take any and all action that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit			

Dated \_\_\_\_\_, 2021

Signature(s)<sup>4</sup>

- <sup>1</sup> Please insert the number and class (i.e., Class A or Class B) of Shares registered in your name(s) to which this proxy relates. If no number is inserted, this form of proxy will be deemed to relate to all the shares in the Company registered in your name(s).
- <sup>2</sup> If any proxy other than the Chairman of the AGM is preferred, strike out the words “the Chairman of the Annual General Meeting or” and insert the name and address of the proxy desired in the space provided. A shareholder may appoint one or more proxies to attend and vote in his stead. Any alteration made to this form of proxy must be initialed by the person(s) who sign(s) it.
- <sup>3</sup> IMPORTANT: If you wish to vote for a particular resolution, tick the appropriate box marked “for”. If you wish to vote against a particular resolution, tick the appropriate box marked “against”. If you wish to abstain from voting on a particular resolution, tick the appropriate box marked “abstain”.
- <sup>4</sup> This form of proxy must be signed by you or your attorney duly authorized in writing or, in the case of a corporation, must be either under seal or executed under the hand of an officer or attorney duly authorized to sign the same.